Catalyst Event
Yuhan Corp (000100) · Other
From Akros SCHK HK-Korea Cosmetics Index (ASHKCOS)
5/29/2026, 12:00:00 AM
Receipt of IND approval from the Korean Ministry of Food and Drug Safety for Phase 1 clinical trial of YH25724, with an estimated 1-5% price impact as an early-stage milestone, expected.
Korean Translation
식품의약품안전처로부터 MASH 치료제 후보물질 'YH25724'의 국내 1상 IND 승인에 따른 1-5%의 주가 영향이 예상됨.
Related Recent Events
Hanwha Corp (000880) · Trading Issue
Trading suspension for Hanwha Corp shares is scheduled to begin on 2026-07-30 in connection with the corporate spin-off, with trading expected to resume on 2026-08-25 upon relisting of Hanwha Corp and listing of the spun-off entity.
7/30/2026, 12:00:00 AM
Hanwha Corp (000880) · Trading Issue
Hanwha Corp confirmed a corporate spin-off creating Hanwha Machinery & Service Holdings (tentative name), separating the tech and life solutions businesses from the surviving Hanwha Corp, which will retain defense, energy, finance and related core businesses. The action also entails a scheduled trading suspension and distribution of new shares to existing holders.
7/30/2026, 12:00:00 AM
HLB Co Ltd (028300) · Other
The U.S. FDA's final decision on the New Drug Application (NDA) for the Rivoceranib and Camrelizumab combination therapy as a first-line treatment for liver cancer is expected by the PDUFA date of July 23, 2026; this major binary event is expected to have a high price impact expected
7/23/2026, 12:00:00 AM
Samchundang Pharm Co Ltd (000250) · Other
An extraordinary general meeting of shareholders to appoint a new outside director on June 30, 2026, scheduled. Low impact estimated as the appointment of an outside director is a routine administrative matter.
6/30/2026, 12:00:00 AM
Hansoh Pharmaceutical Group Company Limited (3692) · Other
Annual General Meeting on June 26, 2026, to approve 2025 results and dividends. Analysts estimate a 1-5% price impact for this routine corporate event scheduled.
6/26/2026, 12:00:00 AM
Celltrion Inc (068270) · Trading Issue
Bonus issue of 0.05 new shares per common share. The ex-rights date was June 4, 2026, with the new shares scheduled to be listed on June 30, 2026.
6/4/2026, 12:00:00 AM